Anzeige
Mehr »
Montag, 18.05.2026 - Börsentäglich über 12.000 News
China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
329 Leser
Artikel bewerten:
(2)

Suvoda LLC: Suvoda introduces agentic RTSM, cutting clinical trial start-up timelines by up to 80%

Next-generation, AI-powered Randomization and Trial Supply Management system-designed to get studies to first-patient-in significantly faster

CONSHOHOCKEN, Pa., April 21, 2026 /PRNewswire/ -- Getting a clinical trial from contract to go-live can take months. For sponsors working to deliver therapies to patients who need them, the startup window is one of the most persistent drags on timelines-and one of the hardest to compress.

Today, Suvoda, a global clinical trial technology company and a recognized leader in the RTSM space, announced agentic RTSM: the next evolution of Suvoda IRT that uses agentic AI to take a study from project kickoff to User Acceptance Testing (UAT) in as little as two weeks.

Agentic RTSM is part of a broader AI strategy that, together with Suvoda's AI assistant Sofia, delivers three outcomes for sponsors and study teams:

  • Accelerate study builds and startup timelines-reducing the kickoff to UAT timeline by up to 80%
  • Elevate the experience for sponsors and sites-giving faster access to trial information and reducing administrative burden
  • Deliver intelligent insights-giving study teams clearer visibility into trial status and smarter decision-making support

In Suvoda RTSM, multiple AI agents accelerate distinct phases of the study build-including software configuration, customization, and testing-and speed up change orders. Because agentic RTSM is built on the patented Suvoda Platform, it leverages the Virtual Partition architecture and the code generation capabilities of the platform's low-code/no-code tools, rather than rebuilding from scratch for each build. It also drives rapid agentic setup through access to a shared data layer with comprehensive data on trial configurations that have been refined through Suvoda's experience with thousands of complex trials. This approach allows Suvoda's team to focus where it matters most: delivering expert consulting and calm guidance at every stage of the trial.

"Clinical trials are only becoming more complex and more urgent, and our customers shouldn't have to deal with technology that slows them down," said Jagath Wanninayake, CEO, Suvoda. "With agentic RTSM, we're using AI to remove friction from trial startup-so sponsors can begin enrolling patients sooner, sites get a smarter and more responsive experience, and study teams spend less time on administrative tasks and more time on the work that matters."

Suvoda is currently working with a select group of early adopters to deploy agentic RTSM capabilities, solidifying the operational and services foundation to support broader rollout. Suvoda is also enhancing Sofia, its AI assistant, to support monitoring, provide alerts, and take direct actions with appropriate safeguards to support the study process. The company plans to extend the agentic model to eCOA and its financial services products, bringing the same startup speed and consistency to questionnaire-based studies, to participant travel, and to patient and site payments.

"Our goal is to make every moment in a trial smarter-whether we're building a complex RTSM system for a study, responding to a protocol amendment, or helping a site coordinator get the right answer in seconds," said E.K. Koh, Chief Product Officer, Suvoda. "Agentic RTSM is one of the first steps in a broader AI vision. Speed, quality, and experience don't have to be trade-offs-they can all move forward together."

At the heart of Suvoda RTSM is a commitment to the people it serves: the sponsors testing new treatments, the sites running trials, and ultimately the patients waiting for therapies. Faster startup isn't just an operational metric-it's a step toward getting medicines to the people who need them sooner.

ABOUT SUVODA

Suvoda is a global clinical trial technology company with a market-leading, real-time software platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company maintains customer satisfaction scores that consistently exceed the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 6,000 trials across more than 115 countries. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com and follow Suvoda on LinkedIn.

CONTACT:

Robin Abadía
Director, External Communications
marketing@suvoda.com

Logo - https://mma.prnewswire.com/media/1759317/5919669/Suvoda_updated_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/suvoda-introduces-agentic-rtsm-cutting-clinical-trial-start-up-timelines-by-up-to-80-302747770.html

© 2026 PR Newswire
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.